Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus
| Autor: | Ruggenenti, P, Lauria, G, Iliev, IP, Fassi, A, Ilieva, AP, Rota, S, Chiurchiu, C, Barlovic, DP, Sghirlanzoni, A, Lombardi, R, Penza, P, CAVALETTI, GUIDO ANGELO, Piatti, ML, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, AR, TREVISAN, ROBERTO, Remuzzi, G, DEMAND Study Investigators, Parvanova, IA, Petrov, II, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Cavaletti, G, Marzorati, L, MARMIROLI, PAOLA LORENA, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, GA, Ganeva, M, Cannata, AN, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, Gardini, F, Lauria, G. |
|---|---|
| Přispěvatelé: | Ruggenenti, P, Lauria, G, Iliev, I, Fassi, A, Ilieva, A, Rota, S, Chiurchiu, C, Barlovic, D, Sghirlanzoni, A, Lombardi, R, Penza, P, Cavaletti, G, Piatti, M, Frigeni, B, Filipponi, M, Rubis, N, Noris, G, Motterlini, N, Ene Iordache, B, Gaspari, F, Perna, A, Zaletel, J, Bossi, A, Dodesini, A, Trevisan, R, Remuzzi, G, DEMAND Study, I, Parvanova, I, Petrov, I, Yakymchuk, S, Arnoldi, F, Prandini, S, Kocijancic, A, Pongrac, D, Prezelj, J, Gala, T, Kersnik, M, Trevisan, G, Lepore, G, Mondo, E, Inversi, F, Mangili, R, Bruno, S, Brusegan, V, Lecchi, V, Belviso, A, Genovese, S, Pareyson, D, Camozzi, F, Marzorati, L, Marmiroli, P, Mattavelli, L, Tadini, S, Gherardi, G, Calini, W, Diadei, O, Rossoni, D, Villa, D, Carminati, S, Agus, E, Remuzzi, A, Giuliano, G, Ganeva, M, Cannata, A, Carrara, F, Cella, C, Centemeri, E, Ferrari, S, Petrò, C, Savoldelli, E, Stucchi, N, Boccardo, P, Perico, N, Peracchi, S, Gelmi, S, Mecca, G, Imbimbo, B, Alberici, M, Gardini, F |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Blood Glucose Male Dihydropyridines medicine.medical_specialty Diabetic neuropathy Urology Renal function Delapril Angiotensin-Converting Enzyme Inhibitors Kidney Function Tests Placebo Risk Assessment Severity of Illness Index Drug Administration Schedule Piperazines Body Mass Index Manidipine Double-Blind Method Internal medicine Diabetes mellitus Internal Medicine medicine Humans Diabetic Nephropathies Nitrobenzenes Aged Dose-Response Relationship Drug diabetes business.industry Hazard ratio Middle Aged Calcium Channel Blockers Prognosis medicine.disease Survival Rate Treatment Outcome Endocrinology Diabetes Mellitus Type 2 Hypertension Indans Albuminuria Drug Therapy Combination Female medicine.symptom business medicine.drug |
| Zdroj: | Hypertension. 58:776-783 |
| ISSN: | 1524-4563 0194-911X |
| DOI: | 10.1161/hypertensionaha.111.174474 |
| Popis: | To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria 2 (IQR: 0.16–0.50 mL/min per 1.73 m 2 ) on combined therapy, 0.36 mL/min per 1.73 m 2 (IQR: 0.18–0.53 mL/min per 1.73 m 2 ) on delapril, and 0.30 mL/min per 1.73 m 2 (IQR: 0.12–0.50 mL/min per 1.73 m 2 ) on placebo ( P =0.87 and P =0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04–0.78; P =0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07–0.99; P =0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24–0.87; P =0.017) and 0.52 (0.27–0.99; P =0.048), respectively. Glucose disposal rate decreased from 5.8±2.4 to 5.3±1.9 mg/kg per min on placebo ( P =0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|